| [1] |
Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014(6):99-109.
|
| [2] |
Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic options[J]. World J Gastroenterol, 2015, 21(43):12211-12217.
|
| [3] |
Christofi T, Baritaki S, Falzone L, et al. Current perspectives in cancer immunotherapy[J]. Cancers, 2019, 11(10):1472.
|
| [4] |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024):1565-1570.
|
| [5] |
Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab[J]. Cell, 2017, 171(4):934-949, e16.
|
| [6] |
Landskron G, De la Fuente M, Thuwajit P, et al. Chronic inflammation and cytokines in the tumor microenvironment[J].J Immunol Res, 2014:149185.
|
| [7] |
somoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells[J]. Hepatology, 2005, 42(6): 1329-1338.
|
| [8] |
Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells[J]. Cancer Res, 2004, 64(10):3517-3524.
|
| [9] |
Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer[J]. Br J Cancer, 2013, 109(10):2665-2674.
|
| [10] |
Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2016, 23(8):2610-2617.
|
| [11] |
Lim YJ, Koh J, Kim K, et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy[J]. Radiother Oncol, 2015, 117(1):165-170.
|
| [12] |
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9):1003-1010.
|
| [13] |
Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets[J]. J Gastrointest Oncol, 2019,10(4):652-662.
|
| [14] |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349):409-413.
|
| [15] |
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26):2455-2465.
|
| [16] |
Kim R, Chung V, Alese OB, et al. A Phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancers[J]. JAMA Oncol, 2020, 6(6):888-894.
|
| [17] |
Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma[J]. Clin Cancer Res, 2010,16(24):6122-6131.
|
| [18] |
Higuchi R, Yamamoto M, Hatori T, et al. Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case[J]. Surg Today, 2006, 36(6):559-562.
|
| [19] |
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer[J]. Science, 2014, 344(6184):641-645.
|
| [20] |
Shimizu K, Kotera Y, Aruga A, et al. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2012, 19(2):171-178.
|
| [21] |
Schlom J, Gulley JL. Vaccines as an integral component of cancer immunotherapy[J]. JAMA, 2018, 320(21):2195-2196.
|
| [22] |
Banchereau J, Palucka K. Immunotherapy: cancer vaccines on the move[J]. Nat Rev Clin Oncol, 2018, 15(1):9-10.
|
| [23] |
Qi XW, Zhang F, Wu H, et al. Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis[J]. Sci Rep, 2015(5):8924.
|
| [24] |
Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination:a new approach for advanced cancer as therapeutic cancer vaccine[J]. Cancer Immunol Immunother, 2013, 62(5):919-929.
|
| [25] |
Yoshitomi M, Yutani S, Matsueda S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis[J]. Exp Ther Med, 2012, 3(3):463-469.
|
| [26] |
Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors[J]. Cancer Ther, 2008, 6(B):955-964.
|
| [27] |
Kobayashi M, Sakabe T, Abe H, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer[J]. J Gastrointest Surg, 2013, 17(9):1609-1617.
|
| [28] |
Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway[J]. Nat Genet, 2014, 46(8):872-876.
|